Person:
KESKİN, YAŞAR

Profile Picture
Google ScholarScopusORCIDPublons
Status
Organizational Units
OrgUnit Logo
Organizational Unit
Job Title
First Name
YAŞAR
Last Name
KESKİN
Name
Email Address
Birth Date

Filters

2020 - 202221
Reset filters

Settings

Start date: 2020 × End date: 2023 × Type: Article ×

Search Results

Now showing 1 - 10 of 21
  • Thumbnail Image
    PublicationOpen Access
    The impact of COVID-19 on familial Mediterranean fever: a nationwide study
    (2021-05-25T00:00:00Z) Günendi, Zafer; Yurdakul, Fatma Gül; Bodur, Hatice; Cengiz, Ahmet Kıvanç; Uçar, Ülkü; Çay, Hasan Fatih; Şen, Nesrin; Keskin, Yaşar; Gürer, Gülcan; Melikoğlu, Meltem Alkan; Altıntaş, Duygu; Deveci, Hülya; Baykul, Merve; Nas, Kemal; Çevik, Remzi; Karahan, Ali Yavuz; Toprak, Murat; Ketenci, Sertaç; Nayimoğlu, Mehmet; Sezer, İlhan; Demir, Ali Nail; Ecesoy, Hilal; Duruöz, Mehmet Tuncay; Yurdakul, Ozan Volkan; Sarıfakıoğlu, Ayşe Banu; Ataman, Şebnem; KESKİN, YAŞAR; YURDAKUL, OZAN VOLKAN
    The study aimed to evaluate the impact of the coronavirus disease 2019 (COVID-19) in patients with familial Mediterranean fever (FMF) and to assess the relationships between FMF characteristics and severe COVID-19 outcomes such as hospitalization. The study was planned within a national network of 21 different centers. Demographics, FMF-related clinical and genetic characteristics, and COVID-19 outcomes were obtained. A total of 822 patients with FMF (mean age of 36 years) were included in the study. Fifty-nine of them (7%) had a COVID-19 diagnosis confirmed by real-time PCR test or chest CT findings. Most FMF patients with COVID-19 (58) had mild and moderate disease activity. All patients were on colchicine treatment. However, 8 of them (13.6%) were not compliant with colchicine use and 9 of them (15.3%) were colchicine resistant. Twelve FMF patients with COVID-19 were hospitalized. There were 4 patients requiring oxygen support. COVID-19 related complications were observed in 2 patients (1 thromboembolism, 1 acute respiratory distress syndrome). Hospitalized COVID-19 patients with FMF were older than non-hospitalized patients (median ages: 51 and 31 years, respectively; p: 0.002). Other FMF-related characteristics were similar between the groups. FMF-related characteristics were not found to be associated with poor outcomes in COVID-19. Thus, FMF may not be a risk factor for poor COVID-19 outcomes.
  • No Thumbnail Available
    PublicationMetadata only
    Clinical course and prognostic factors of COVID-19 infection in patients with chronic inflammatory-rheumatic disease: A retrospective, case-control study
    (2022-09-01T00:00:00Z) Nas, Kemal; Guclu, Ertugrul; KESKİN, Yaşar; Dilek, Gamze; Unan, Mehtap Kalcik; Can, Nurselin; Tekeoglu, Ibrahim; Kamanli, Ayhan; KESKİN, YAŞAR
    Objectives: This study aims to investigate the prognosis of novel coronavirus disease-2019 (COVID-19) infection in patients with the chronic inflammatory-rheumatic disease and evaluate the effects of immunosuppressive drugs on the prognosis, clinical characteristics, laboratory findings and hospitalization periods of the rheumatic patients with COVID-19 infection. Patients and methods: Between April 2020 and March 2021, a total of 101 patients (30 males, 71 females; mean age: 48±14.4 years; range, 46 to 48 years) with the rheumatic diseases diagnosed with COVID-19 infection were included. A total of 102 age- and sex-matched patients (35 males, 67 females; mean age: 44±14.4 years; range, 28 to 44 years) who were diagnosed with COVID-19 infection and had no history of rheumatic disease in the same period were included as the control group. Data including demographic characteristics of the patients, presence of any symptoms of COVID-19 disease, laboratory data at the time of diagnosis, and treatments administered were collected. Results: The rate of hospitalization was higher in 38 (37%) patients without rheumatic diseases than in 31 (31%) patients with rheumatic diseases (p=0.324). The rate of lung infiltration on radiographic examination was higher in patients without rheumatic diseases (40% vs. 49%) (p=0.177). COVID-19 infection symptoms such as anosmia 45 (45%), ageusia 51 (50%), shortness of breath 45(45%), nausea 29 (29%), vomiting 16 (16%), diarrhea 25 (25%) and myalgia-arthralgia 81 (80%) were higher in patients with rheumatic diseases. In terms of laboratory values, lymphocyte count (p=0.031) was statistically higher in patients without rheumatic diseases. Hydroxychloroquine (35%), oseltamivir 10 (10%), antibiotics 27 (26%), acetylsalicylic acid 52 (51%), and supplementary oxygen 25 (25%) treatments which used to cure COVID 19 infection were administered more in patients without rheumatic diseases. The number of treatments administered was higher in patients without rheumatic diseases (p<0.001). Conclusion: Patients with the chronic inflammatory-rheumatic disease have more symptoms due to COVID-19 infection, but the disease course is not poor and hospitalization rates are lower.
  • No Thumbnail Available
    PublicationMetadata only
    Correlation between sitting duration and position and lumbar pain among office workers
    (2021-02-01T00:00:00Z) KEPEKÇİ, MÜGE; AYDIN, TEOMAN; KESKİN, YAŞAR; ÜRKMEZ, BERNA; KESKİN, YAŞAR; AYDIN, TEOMAN
  • No Thumbnail Available
    PublicationMetadata only
    THE IMPACT OF SOCIOECONOMIC STATUS ON CLINICAL PARAMETERS IN FEMALE PSA PATIENTS
    (2021-09-01T00:00:00Z) Tekeoglu, I.; Nas, K.; KESKİN, Yaşar; Kilic, E.; Sargin, B.; Kasman, Acer S.; Alkan, H.; Sahin, N.; Cengiz, G.; Cuzdan, N.; Gezer, Albayrak; Keskin, D.; Mulkoglu, C.; Resorlu, H.; Ataman, S.; Hasturk, Bal A.; Duruoz, Tuncay M.; Kucukakkas, O.; Yurdakul, Volkan O.; Melikoglu, Alkan M.; Ayhan, Figen F.; Baykul, M.; Bodur, H.; Calis, M.; Capkin, E.; Devrimsel, G.; Ecesoy, H.; Gok, K.; Hizmetli, S.; Kamanli, A.; Kutluk, O.; Sen, N.; Sendur, Faruk O.; Toprak, M.; Tolu, S.; Tuncer, T.; KESKİN, YAŞAR; YURDAKUL, OZAN VOLKAN
  • No Thumbnail Available
    PublicationMetadata only
    Evaluation of hepatitis serology and frequency of viral reactivation in patients with inflammatory arthritis receiving biologic agents: a multicenter observational study
    (2022-09-01T00:00:00Z) ÇAPKIN, ERHAN; YAZICI, ALİ; KARKUCAK, MURAT; Durmaz, Yunus; Toprak, Murat; ATAMAN, ŞEBNEM; Sahin, Nilay; Cuzdan, Nihan; Kasapoglu Aksoy, Meliha; Onder, Mustafa Erkut; Serdaroglu Beyazal, Munevver; Mesci, Nilgun; Baykul, Merve; Alkan Melikoglu, Meltem; Alkan, Hakan; Dulgeroglu, Deniz; Cengiz, Ahmet Kivanc; Nas, Kemal; Balevi Batur, Elif; Caliskan Uckun, Asli; Deveci, Hulya; Erol, Kemal; Albayrak Gezer, Ilknur; Akgol, Gurkan; Duruoz, Mehmet Tuncay; Kucukakkas, Okan; Sarikaya, Selda; Rezvani, Aylin; Atan, Tugba; Gogus, Feride; Caglayan, Gokhan; KESKİN, Yaşar; Bulut Keskin, Ayse Selcen; Oz, Nuran; Yilmaz, Gurdal; KESKİN, YAŞAR
    To evaluate of hepatitis serology and reactivation frequency in patients with rheumatic disease receiving biologic agents. Our study included patients with inflammatory rheumatic diseases from 23 centers, who were followed up with biological therapy. Demographic and clinical characteristics of the patients, duration of drug use and hepatitis serology and the state of viral reactivation were analyzed. A total of 4060 patients, 2095 being males, were included in our study. Of the patients, 2463 had Ankylosing Spondylitis (AS), 1154 had Rheumatoid Arthritis (RA), 325 had Psoriatic Arthritis (PsA), and 118 had other inflammatory rheumatic diseases. When the viral serology of the patients was evaluated, 79 patients (2%) who were identified as HBs Ag positive, 486 (12%) patients who were HBs Ag negative and anti-HBc IgG positive and 20 patients (0.5%) who were anti-HCV positive. When evaluated on a disease-by-disease basis, the rate of HBsAg was found to be 2.5% in RA, 2% in AS and 0.9% in PsA. Viral reactivation was detected in 13 patients while receiving biologic agents. HBs Ag was positive in nine patients with reactivation and negative in four patients. Anti-HBc IgG, however, was positive. Six of these patients had AS, four had RA, and three had PsA. The development of hepatitis reactivation in 11.4% of HBs Ag positive patients and 0.82% of anti-HBc IgG positive patients due to the use of biologic agents is an important problem for this group of patients. Antiviral prophylaxis is recommended to be started especially in patients who are HBs Ag positive and who are using biologic agents due to viral reactivation. Therefore, it is important to carry out hepatitis screenings before biologic agent treatment and to carefully evaluate the vaccination and prophylaxis requirements.
  • No Thumbnail Available
    PublicationMetadata only
    Coexistence of fibromyalgia and metabolic syndrome in females: The effects on fatigue, clinical features, pain sensitivity, urinary cortisol and norepinephrine levels: A cross-sectional study
    (2021-03-01T00:00:00Z) KESKİN, Yaşar; Nas, Kemal; Kilic, Erkan; Sargin, Betul; Kasman, Sevtap Acer; Alkan, Hakan; Sahin, Nilay; CENGİZ, GİZEM; Cuzdan, Nihan; Gezer, Ilknur Albayrak; Keskin, Dilekk; Mulkoglu, Cevriye; Resorlu, Hatice; Ataman, Sebnem; Bal, Ajda; Duruoz, Mehmet Tuncay; Kucukakkas, Okan; YURDAKUL, Ozan Volkan; Melikoglu, Meltem Alkan; Aydin, Yildiray; Ayhan, F. Figen; Bodur, Hatice; Calis, Mustafa; Capkin, Erhan; Devrimsel, Gul; Gok, Kevser; Hizmetli, Sami; Kamanli, Ayhan; Ecesoy, Hilal; Kutluk, Oznur; Sen, Nesrin; Sendur, Omer Faruk; Tekeoglu, Ibrahim; Tolu, Sena; Toprak, Murat; Tuncer, Tiraje; KESKİN, YAŞAR; KÜÇÜKAKKAŞ, OKAN; YURDAKUL, OZAN VOLKAN
    Objectives: This study aims to evaluate the coexistence of metabolic syndrome (MetS) and fibromyalgia syndrome (FMS) and determine the effects of this coexistence on neuroendocrine levels and clinical features of FMS.
  • No Thumbnail Available
    PublicationMetadata only
    Impact of obesity on quality of life, psychological status, and disease activity in psoriatic arthritis: a multi‑center study.
    (2021-08-28T00:00:00Z) Gok, Kevser; Nas, Kemal; Tekeoglu, Ibrahim; Sunar, Ismihan; Kilic, Erkan; Sargin, Betul; Acer Kasman, Sevtap; Alkan, Hakan; Sahin, Nilay; Cengiz, Gizem; Cuzdan, Nihan; Albayrak Gezer, İlknur; Keskin, Dilek; Mulkoglu, Cevriye; Resorlu, Hatice; Bal, Ajda; Duruoz, Mehmet Tuncay; Yurdakul, Ozan Volkan; Alkan Melikoglu, Meltem; Aydin, Yildiray; Ayhan, Fikriye Figen; Bodur, Hatice; Calis, Mustafa; Capkin, Erhan; Devrimsel, Gul; Ecesoy, Hilal; Hizmetli, Sami; Kamanli, Ayhan; Kutluk, Oznur; Kucukakkas, Okan; Sendur, Omer Faruk; Tolu, Sena; Toprak, Murat; Tuncer, Tiraje; KESKİN, YAŞAR; KÜÇÜKAKKAŞ, OKAN; YURDAKUL, OZAN VOLKAN
  • No Thumbnail Available
    PublicationMetadata only
    Evaluation of the Relationship Between Anxiety, Obsessive-Compulsive Disorder and Clinical Parameters in Patients with Young Knee Osteoarthritis
    (2022-01-01T00:00:00Z) Gürcan Atçı, Aysel; KESKİN, YAŞAR; BAĞ, SEVDA; KESKİN, YAŞAR
  • No Thumbnail Available
    PublicationMetadata only
    Inconsistencies of the Disease Activity Assessment Tools for Psoriatic Arthritis: Challenges to Rheumatologists.
    (2021-10-14T00:00:00Z) Gezer, Halise Hande; Duruöz, Mehmet Tuncay; Nas, Kemal; Kılıç, Erkan; Sargın, Betül; Kasman, Sevtap Acer; Alkan, Hakan; Şahin, Nilay; Cengiz, Gizem; Cüzdan, Nihan; Gezer, İlknur Albayrak; Keskin, Dilek; Mülkoğlu, Cevriye; Reşorlu, Hatice; Sunar, İsmihan; Bal, Ajda; Küçükakkaş, Okan; Yurdakul, Ozan Volkan; Melikoğlu, Meltem Alkan; Baykul, Merve; Ayhan, Fikriye Figen; Bodur, Hatice; Çalış, Mustafa; Çapkın, Erhan; Devrimsel, Gül; Gök, Kevser; Hizmetli, Sami; Kamanlı, Ayhan; Keskin, Yaşar; Ecesoy, Hilal; Kutluk, Öznur; Şen, Nesrin; Şendur, Ömer Faruk; Tekeoğlu, İbrahim; Tolu, Sena; Toprak, Murat; Tuncer, Tiraje; KÜÇÜKAKKAŞ, OKAN; YURDAKUL, OZAN VOLKAN; KESKİN, YAŞAR
  • Thumbnail Image
    PublicationOpen Access
    What Has Changed in the Treatment of Psoriatic Arthritis After COVID-19?
    (2021-06-01T00:00:00Z) KESKİN, Yaşar; Koz, Gokhan; Nas, Kemal; KESKİN, YAŞAR
    Coronavirus disease 2019 is a respiratory infection caused by severe acute respiratory syndrome coronavirus 2. Coronavirus disease 2019 leads to the rapid activation of innate immune cells, particularly in patients with severe disease. Psoriatic arthritis is a heterogeneous chronic inflammatory disease characterized by the association of psoriasis and arthritis. Similar to those with other viruses, patients with psoriatic arthritis are at a significant risk of infection with severe acute respiratory syndrome coronavirus 2. Patients with psoriatic arthritis are immunosuppressed owing to immune dysregulation during the active disease period or owing to immunosuppressive drugs administered during remission, and they are prone to infections. The severe acute respiratory syndrome coronavirus 2 is a threat to millions of people globally owing to the decline in immunity and because a significant number of people develop severe illness. In the period of coronavirus disease 2019 pandemic, we briefly present recommendations for the treatment of psoriatic arthritis. In this review, we briefly address the management options and treatment recommendations for patients with psoriatic arthritis during and after the coronavirus disease 2019 pandemic in light of recent scientific publications.